Next-generation Sequencing Data Analysis Market - Databook 2025 to 2034

The global next-generation sequencing data analysis market size was estimated at USD 1,002 million in 2024 and is projected to be worth around USD 8,072 million by 2034, growing at a CAGR of 23.20% from 2025 to 2034.

Highlights of the Next-generation Sequencing Data Analysis Market

• North America dominated the global next-generation sequencing data analysis market in 2024.
• Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
• By product, the services segment held a dominant presence in the market in 2024.
• By product, the commercial NGS software segment is expected to grow at the fastest rate in the market during the forecast period.
• By workflow, the NGS tertiary data analysis segment dominated the market in 2024.
• By workflow, the NGS secondary data analysis segment is projected to experience the highest growth rate in the market.
• By mode, the in-house data analysis segment led the market.
• By mode, the outsourced data analysis segment is expected to grow at the fastest rate in the market during the forecast period.
• By read length, the short-read sequencing segment dominated the market in 2024.
• By read length, the very long-read sequencing segment is expected to grow at the fastest rate in the market during the forecast period.
• By end use, the academic research segment dominated the market in 2024.
• By end use, the pharma & biotech entities segment is expected to grow at the fastest rate in the market during the forecast period.

Industry Valuation and Growth Rate Projection

The next-generation sequencing data analysis market deals with the management and use of data generated using next-generation sequencing (NGS). Next-generation sequencing is a potent tool widely used in genomics research. It is used to sequence a large number of DNA fragments at a time, offering detailed information about the structure of genomes, genetic variations, changes in behavior, and any activity. Recent developments have enabled faster and more precise sequencing, lowered expenses, and enhanced data determination. These biotech advances are promising for researchers to unlock the latest insights into genomics and enhance the grip of disorders and customized healthcare.

Next-generation Sequencing Data Analysis Market: Stats and Figures

• The UK Biobank (UKBB) study has been ongoing since 2015. The massive and detailed prospective study has looked at over 500,000 participants aged 40–69 years when recruited in 2006–2010. UKBB collected both genotypic and phenotypic information about the participants, including data about physical measures, sample assays, and other health-related data.
• The last two years have seen significant strides in improving NGS data analysis. Advanced short-read sequencers are on track to achieve the Q40 standard, which denotes one error in 10,000 bases.

How AI Has Benefitted the Next-generation Sequencing Data Analysis Market

• NGS data determination is understanding genetic variants, like insertions and deletions (indels) or single nucleotide polymorphisms (SNPs). These variants can signify disease, and precisely analyzing them is vital.
• AI algorithms determine gene expression profiles, assisting to determine differentially expressed genes over conditions or disorder states. AI models can easily interpret huge amounts of expression data, determining patterns that would or else be hidden in the noise.
• NGS technologies can showcase sequencing errors, mainly in areas with highly complex or repetitive sequences. Manually accessing these errors is a lengthy and inefficient process. Machine learning models can somehow be skilled to differentiate between sequencing noise and actual biological variation.

Industry Leader Announcements

• Mark Li, Resolution Bioscience president and CEO, Agilent Technologies Inc.

“Agilent’s broad expertise, global regulatory and commercial infrastructure, extensive partnerships with biopharma companies, and decades-long leadership in precision medicine will enhance and accelerate our groundbreaking work,” said Mark Li, Resolution Bioscience president and CEO. “We are excited to further expand the use of NGS in precision oncology for clinical diagnostics as part of the Agilent team.”

• Dominic John, Vice President, QIAGEN Digital Insights.

With the opening of this data center, we are strengthening our ability to serve the Australian market and the broader Australia/Asia-Pacific region,” said Dominic John, Vice President, QIAGEN Digital Insights.” This new facility will allow diagnostic labs to deliver clinical next-generation sequencing testing services confidently while meeting evolving data sovereignty laws. Now operating eight data centers around the globe, we are ensuring data security, compliance, and operational excellence worldwide.”

Geographical Insights

The global next-generation sequencing data analysis market is undergoing remarkable growth, with North America holding its position as the dominant region. Meanwhile, Europe is quickly evolving into the fastest-growing market. In the Asia-Pacific, China stands out as a significant growth country in the space.

North America

North America dominated the next-generation sequencing data analysis market in 2024. Next-generation sequencing needs advanced infrastructure, technological fund, and trained personnel, which improves the overall expenses of sequencing. Pharmaceutical firms and healthcare professionals depend on next-generation sequencing professionals, which is anticipated to drive the need for NGS services in North America.

Europe

Europe is projected to be the fastest-growing region in the market. The increasing interest in the clinical importance of NGS diagnostics does not work with the sensitivity of legislative.

frameworks and the accessibility of evidence-derived expense-effectiveness analyses. This supports the NGS incorporation in the national healthcare domain out of step with the increasing requirement for customized medicine. From an organizational perspective, different healthcare settings select outsourced or in-house solutions, each with its own financial and logistic solutions.

China and APAC

The Asia Pacific (APAC) region is experiencing rapid growth in the next-generation sequencing data analysis market. China stands out as the fastest-growing within APAC. Next-generation sequencing technology is able to sequence millions and many billions of DNA molecules constantly. The China Actionable Genome Consortium (CAGC), at present an expertise group, states advisory guidelines on clinical usages of NGS technology for the determination of cancer driver genes for accurate cancer therapy. This group includes an assembly of clinical oncologists, laboratory cancer geneticists, bioinformaticians, and other professionals.

Recent Developments

• In October 2024, MiLaboratories is thrilled to disclose the success of its Series A funding round, contributed by Madrid-based Kfund and with some additional backing from Speedinvest and most established international investors.
• In May 2024, Bio-IT firm Molecular Health and Integrated DNA Technologies (IDT) signed a multi-year agreement globally to incorporate their next-generation sequencing (NGS) abilities.

Competitive Landscape

The next-generation sequencing data analysis market is influenced by various pharmaceutical firms renowned for their notable allowance for research and treatment. Depending upon recent information, the major three leading firms are:

• Company Name: Thermo Fisher Scientific, Inc.
• Year of Incorporation: 2004
• Headquarters: Waltham, Massachusetts, US

Thermo Fisher Scientific holds a key position in the area of scientific instruments and services. With a large portfolio of creative products and solutions, the firm has established itself as a leader in offering the latest technology for research laboratories globally.

• Company Name: Eurofins Scientific
• Year of Incorporation: 1987
• Headquarters: Luxembourg

Eurofins Scientific is a complex web of opportunities and challenges in the developing world of scientific analysis and testing. As one of the important manufacturers of bioanalytical testing services, Eurofins has to face fierce competition from a distinctive player vying for a share in domains ranging from food safety and pharmaceuticals.

• Company Name: Agilent Technologies Inc.
• Year of Incorporation: 1852
• Headquarters: Santa Clara, California, United States

Agilent Technologies functions in a highly competitive landscape, continually attempting to innovate and stay focused on the curve in the quickly evolving world of scientific and analytical instrumentation. With a robust aim on research and development, Agilent has demonstrated itself as a dominating provider of the latest solutions for a broader range of domains, from environmental and healthcare testing.